Last reviewed · How we verify
Dexamethasone, 0.4mg
At a glance
| Generic name | Dexamethasone, 0.4mg |
|---|---|
| Also known as | OTX-DP, dextenza |
| Sponsor | Ocular Therapeutix, Inc. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dextenza Versus Topical Steroid Eye Drops for Postoperative Management Following Corneal Crosslinking (PHASE1, PHASE2)
- Dextenza vs Prednisolone Acetate After Cataract Surgery for Patients With Diabetes (PHASE4)
- Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery (PHASE4)
- Adjunctive Doxycycline for Central Nervous System Tuberculosis (PHASE2)
- DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia (EARLY_PHASE1)
- In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery (PHASE4)
- ACCURATE Study for Subjects With Dry Eyes (PHASE4)
- Pharmacokinetics of Aqueous Dexamethasone (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone, 0.4mg CI brief — competitive landscape report
- Dexamethasone, 0.4mg updates RSS · CI watch RSS
- Ocular Therapeutix, Inc. portfolio CI